PathogenDx, Inc.

PathogenDx is a biotechnology company developing diagnostic solutions to address viral, bacterial and fungal infection or contamination. We are expanding the possibilities of molecular testing to identify pathogens faster and easier through our game-changing microarray technology—driving a higher standard of sensitivity and specificity in testing for healthcare and food & agriculture. We deliver innovative solutions that are efficient, robust, that are cost effective and save lives,.

Recent News

  • PathogenDx Unveils Phytox: A New Breakthrough Virus Detection Technology to Curb the Spread of Plant-Born Pathogens in the Cannabis, Food and Agriculture Sectors

    Scottsdale, Arizona--(Newsfile Corp. - September 15, 2022) - PathogenDx ("PathogenDx" or "Company"), a leader in next-generation microarray technology for better health and safety, launched a new breakthrough virus detection technology - Phytox - to help curb the spread of new and existing plant-born pathogens, which are currently on the rise. The new Asymmetric RT-PCR microarray technology for the cannabis, food and agriculture sectors is capable of detecting nine viruses or more in a single test and provides simultaneous, accurate...

    2022-09-15 7:30 AM EDT
  • PathogenDx Inc. Honored on the 2022 Inc. 5000 Annual List

    Scottsdale, Arizona--(Newsfile Corp. - August 16, 2022) - Inc. revealed that PathogenDx ("PathogenDx" or "Company"), a leader in world-class microarray technology to advance molecular testing in human diagnostics, food and agricultural industries, placed No. 1232 on the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. The list takes a one-of-a-kind look at the most successful companies within the economy's most dynamic segment-its independent businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia and many other...

    2022-08-16 7:00 AM EDT
  • PathogenDx Awarded Honorable Mention in the Pandemic Response Category of Fast Company's 2022 World Changing Ideas Awards

    Scottsdale, Arizona--(Newsfile Corp. - May 3, 2022) - PathogenDx ("PathogenDx" or "Company"), a U.S.-based biotechnology company setting the standard in molecular-based testing through the widespread adoption of its advanced microarray testing platform for the human diagnostics, food and agricultural industries, announced that it has been awarded an honorable mention in Fast Company's 2022 World Changing Ideas Awards in the "Pandemic Response" category for its introduction of a new, customized COVID-19 testing portal, which rapidly and affordably detects all SARS-CoV-2 variants...

    2022-05-03 8:00 AM EDT
  • PathogenDx's Receives Industry-First AOAC Certification to Detect Bacterial and Fungal Species in a Single Well Test for Cannabis Matrices

    Introduction of Another Major Advancement in Cannabis Testing Technologies by PathogenDx to Help Meet Quality and Safety Standards as the Need for Pathogen Testing Continues to Evolve; Protecting Public Health with Testing Accuracy, Speed and Ability to Reduce Manual ErrorsMolecular-Based Testing Technology Has Shortest Processing Time of Any Multiplex Microbial Assay Accepted by a Regulatory Agency Scottsdale, Arizona--(Newsfile Corp. - April 19, 2022) -  PathogenDx ("PathogenDx" or "Company"), a U.S.-based biotechnology company setting the standard in molecular-based testing through widespread adoption of...

    2022-04-19 1:05 PM EDT
  • With a Two-Year Revenue Growth of 252 Percent, PathogenDx Ranks No. 46 on Inc. Magazine's List of the Southwest Region's Fastest-Growing Private Companies

    Scottsdale, Arizona--(Newsfile Corp. - March 15, 2022) - Inc. magazine revealed that PathogenDx, a U.S.-based biotechnology company that is setting a new standard in molecular testing through widespread adoption of its advanced microarray testing platform for the human diagnostics, food and agricultural industries, is No. 46 on its third annual Inc. 5000 Regionals Southwest list, the most prestigious ranking of the fastest-growing private companies based in Arizona, New Mexico, Oklahoma and Texas. Born of the annual Inc. 5000 franchise, this...

    2022-03-15 8:30 AM EDT
  • BioTech Company PathogenDx Strengthens Executive Team; Announces Several New Key Leadership Appointments

    Scottsdale, Arizona--(Newsfile Corp. - March 3, 2022) - PathogenDx, a U.S.-based biotechnology company, has bolstered its strategic advisory group and senior leadership team with the appointments of several highly experienced executives who will bring their expertise to the company as it sets a new global standard in molecular-based testing through the widespread adoption of its advanced microarray testing platform for the clinical & human diagnostics, food & agricultural and climate change sectors.PathogenDx's new leadership appointments include: veteran healthcare executive, Clinical...

    2022-03-03 8:00 AM EST
  • Arizona Companies PathogenDx, Formula Diagnostics and Bashas' Food City Offer Safe, Accurate and Fast COVID-19 Testing to Uninsured Arizonans

    Scottsdale, Arizona--(Newsfile Corp. - February 15, 2022) - PathogenDx, a biotechnology company setting the standard in molecular testing, Formula Diagnostics ("FDX"), a provider of clinical laboratories and health services, and Bashas' Food City, a family-owned-and-operated grocer, announced a community service partnership, which is bringing uninsured individuals in Phoenix and Mesa access to COVID-19 testing at no cost. The Arizona-based companies will be dedicating time and volunteering resources to deliver safe, accurate and fast tests

    2022-02-15 7:00 AM EST
  • PathogenDx Announces the CE Marking of Its Next-Generation COVID-19 Testing Technology for the Simultaneous Detection of SARS-CoV-2 (COVID-19) and Its Variants

    Scottsdale, Arizona--(Newsfile Corp. - February 2, 2022) - PathogenDx, a U.S.-based biotechnology company that is setting the standard in molecular testing through the widespread adoption of its innovative DNA microarray testing platform for the human diagnostics, food and agricultural industries, announced that its next-generation COVID-19 test technology, the Detectx-Cv+ test, has been CE marked in accordance with the requirements of the European Parliament and Council Directive 98/79/EC on in vitro diagnostic medical devices

    2022-02-02 6:00 AM EST